Solu Therapeutics Shows Positive Preclinical Data on STX-0712 for Leukemias at ASH Meeting

Solu Therapeutics, a biotechnology company based in Boston, Massachusetts, has announced promising preclinical data for their innovative therapeutic, STX-0712. This new drug, engineered as a CCR2-CyTAC (Cytotoxicity Targeting Chimera), is designed to treat chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML). The announcement was made during the American Society of Hematology (ASH) Annual Meeting held from December 7-10, 2024, in San Diego, California.

The company's Chief Medical Officer, Sergio Santillana, highlighted the potential of their CyTAC platform, which is designed to precisely target and eliminate disease-driving cells. Santillana emphasized that STX-0712 has shown a remarkable ability to selectively target CCR2-positive malignant monocytes in CMML and AML, demonstrating the platform's promise in developing transformative therapies for various types of cancer and other diseases. He expressed optimism about progressing STX-0712 into clinical trials and utilizing their platform to address other high-need diseases.

The preclinical results for STX-0712 in CMML and AML were presented in two poster sessions at the ASH Annual Meeting. The findings demonstrated that STX-0712 exhibited robust activity against CCR2-positive monocytes in patient samples from both CMML and AML. This data suggests that STX-0712 has the potential to become a highly targeted treatment option, addressing the underlying drivers of these cancers while maintaining a strong safety profile.

Brandon Turunen, Co-founder, Chief Technology Officer, and Head of Drug Discovery at Solu, remarked on the significance of these results, noting that they underscore the potential of STX-0712 in treating CMML and AML, both of which have limited targeted therapies available. Turunen expressed enthusiasm about advancing STX-0712 to clinical-stage research in 2025, aiming to offer a more targeted approach to treatment for patients with these challenging blood cancers.

STX-0712 is a CyTAC targeting the G-Protein Coupled Receptor (GPCR) CCR2, a marker expressed at high levels on malignant monocytes that are key drivers in certain hematologic cancers. By focusing on CCR2, STX-0712 is designed to selectively eliminate these malignant cells, potentially providing a more effective and safer treatment option for patients.

Solu Therapeutics is a biotechnology company committed to developing next-generation therapeutics to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas. The company's proprietary CyTAC (Cytotoxicity Targeting Chimera) and TicTAC (Therapeutic Index Control Targeting Chimera) platforms enable the development of innovative medicines that combine the target-binding capability of small molecules with the therapeutic power of biologics. Solu Therapeutics is dedicated to advancing the field of oncology, immunology, and other therapeutic areas by bringing transformative therapies to patients in need.

In summary, Solu Therapeutics' preclinical data for STX-0712 is highly encouraging, showcasing its potential as a targeted treatment for CMML and AML. The company's CyTAC platform appears to be a promising tool in developing therapies that can selectively target and eliminate disease-driving cells. With plans to advance STX-0712 into clinical trials in 2025, Solu Therapeutics continues to make significant strides in the pursuit of innovative treatments for cancer and other diseases.